IMGN ImmunoGen Inc.

-0.21  -4%
Previous Close 5.39
Open 5.34
Price To Book 16.71
Market Cap 772290189
Shares 149,090,770
Volume 1,351,922
Short Ratio
Av. Daily Volume 2,603,057

SEC filingsSee all SEC filings

  1. 8-K - Current report 181201022
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181156036
  3. 8-K - Current report 181155465
  4. CT ORDER - Confidential treatment order 181085573
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18990845

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Feb 22 2013 - under priority review
2nd-line HER2+ Metastatic Breast Cancer
Phase 1b/2 updated data due mid-2019.
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 3 top-line data due 1H 2019.
Mirvetuximab soravtansine - FORWARD I
Cancer - ovarian cancer and relapsed endometrial cancer
Phase 3 trial did not meet endpoints.
Kadcyla KRISTINE trial
HER2-positive breast cancer - neo-adjuvant setting
Endpoint not met - October 2015
Kadcyla GATSBY trial
Cancer - metastatic HER2+ gastric cancer
Phase 3 data due in 2019.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
Phase 3 data released October 15, 2018 met primary endpoint. Data released December 5, 2018 noted HR = 0.50 (reduction of the risk of disease recurrence or death by 50%).
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
Phase 3 data released Dec 18 2014. Met non-inferiority endpoint but did NOT significantly improve PFS compared to Herceptin and chemotherapy
Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla - MARIANNE trial
Cancer - 1st-line HER2+ Metastatic Breast Cancer
Phase 1 data at ASH 2018 noted 6/23 OR; 2/23 CR.
Acute Myeloid Leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Phase 1 additional data due at ASH December 1, 2018 noted 26% ORR; 7% CR.
Relapsed/refractory acute myeloid leukemia (AML)

Latest News

  1. Market Trends Toward New Normal in Marriott International, Duke Energy, ImmunoGen, Newell Brands, Vail Resorts, and Fiserv — Emerging Consolidated Expectations, Analyst Ratings
  2. Roche's Kadcyla Halves Death Risk in Breast Cancer Study
  3. The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
  4. ImmunoGen (IMGN) Down 7.2% Since Last Earnings Report: Can It Rebound?
  5. ImmunoGen Presents New Data Highlighting Potential of Novel ADCs in Oral Presentations at ASH Annual Meeting
  6. The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial
  7. Former Aveo exec resigns as ImmunoGen CFO after fraud verdict
  8. ImmunoGen Announces Resignation of Chief Financial Officer
  9. The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings
  10. Former Aveo CFO misled biotech's investors, jury finds
  11. Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock?
  12. Edited Transcript of IMGN earnings conference call or presentation 2-Nov-18 12:00pm GMT
  13. Healthcare Stocks with Turnaround Potential
  14. How Has Cara Therapeutics’ 2018 Performance Shaken Out?
  15. ImmunoGen Waits to Leap "Forward"
  16. Here's Why ImmunoGen Closed Almost 12% Up on Wednesday
  17. Here's Why ImmunoGen Shares Lost 42.7% in October
  18. ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
  19. How ImmunoGen Inc (NASDAQ:IMGN) Can Impact Your Portfolio Volatility